Jefferies Group Reaffirms Buy (N/A) Rating on Abbott Laboratories (ABT)
Several other analysts have also recently commented on the stock. Analysts at Zacks reiterated a “neutral” rating on shares of Abbott Laboratories in a research note to investors on Monday, May 7th. They now have a $66.00 price target on the stock. Finally, analysts at Bank of America (NYSE: BAC) raised their price target on shares of Abbott Laboratories from $57.00 to $65.00 in a research note to investors on Thursday, April 5th.
Abbott Laboratories opened at 60.30 on Tuesday. Abbott Laboratories has a 1-year low of $46.29 and a 1-year high of $63.20. The company has a market cap of $94.875 billion and a price-to-earnings ratio of 18.62.
Abbott Laboratories last released its earnings data on Wednesday, April 18th. The company reported $1.03 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.00 by $0.03. Abbott Laboratories’s revenue was up 4.6% compared to the same quarter last year. Analysts expect that Abbott Laboratories will post $1.27 EPS next quarter.
Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture, and sale of a range of health care products.